Associated Papers
In Silico Binary Classification of Catalytic Function (Unaffected or Impaired) of Flavin-Containing Monooxygenase 3 (FMO3) Variants and in Vitro Validation Using New Variants Found in a Japanese Genome Resource Database.
Shimizu M et al.
Biological & Pharmaceutical Bulletin, 2025
Exploring Trimethylaminuria: Genetics and Molecular Mechanisms, Epidemiology, and Emerging Therapeutic Strategies.
Sidoti A et al.
Biology, 2024
First Report from Saudi Arabia of Trimethylaminuria Caused by a Premature Stop Codon Mutation in the FMO3 Gene.
Alghanem B et al.
The Application of Clinical Genetics, 2024
Adaptive Modelling of Mutated FMO3 Enzyme Could Unveil Unexplored Scenarios Linking Variant Haplotypes to TMAU Phenotypes.
Alibrandi S et al.
Molecules (basel, Switzerland), 2021
Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease.
Phillips IR et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Extensive disruption of protein interactions by genetic variants across the allele frequency spectrum in human populations.
Fragoza R et al.
Nature Communications, 2019
Targeted sequencing identifies genetic polymorphisms of flavin-containing monooxygenase genes contributing to susceptibility of nicotine dependence in European American and African American.
Zhang TX et al.
Brain and Behavior, 2017
Pharmacogenetic Variation in Over 100 Genes in Patients Receiving Acenocumarol.
Gonzalez-Covarrubias V et al.
Frontiers in Pharmacology, 2017
Trimethylaminuria (fish odor syndrome): genotype characterization among Portuguese patients.
Ferreira F et al.
Gene, 2013
Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities.
Yamazaki H et al.
Biochemical Pharmacology, 2013
Trimethylaminuria: an under-recognised and socially debilitating metabolic disorder.
Christodoulou J
Journal of Paediatrics and Child Health, 2012
A common FMO3 polymorphism may amplify the effect of nicotine exposure in sudden infant death syndrome (SIDS).
Poetsch M et al.
International Journal of Legal Medicine, 2010
Flavin-containing monooxygenase 3 and human disease.
Motika MS et al.
Expert Opinion on Drug Metabolism & Toxicology, 2007
A spectrum of molecular variation in a cohort of Italian families with trimethylaminuria: identification of three novel mutations of the FM03 gene.
Teresa E et al.
Molecular Genetics and Metabolism, 2006
The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development.
Cashman JR
Drug Discovery Today, 2004
Trimethylaminuria and a human FMO3 mutation database.
Hernandez D et al.
Human Mutation, 2003
Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation.
Cashman JR et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2002
Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FM03) gene in patients with fish-odour syndrome.
Dolphin CT et al.
Pharmacogenetics, 2000